<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621070</url>
  </required_header>
  <id_info>
    <org_study_id>JS002-007</org_study_id>
    <nct_id>NCT05621070</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized,&#xD;
      double-blind, placebo-controlled study to evaluate the efficacy, safety, PK/PD profile,&#xD;
      immunogenicity as well as complete delivery of auto-injector by patients of JS002 as&#xD;
      monotherapy in patients with primary hypercholesterolaemia and mixed dyslipidemia.&#xD;
&#xD;
      In this study, two dose cohorts(150 mg, 450 mg) are set up, and 582 subjects are planned to&#xD;
      be enrolled (randomizedly assigned to JS002 or placebo 150/450 mg group in a 2:1:2:1 ratio).A&#xD;
      screening period (≤6 weeks), a double-blind treatment period (12 weeks), an open-label&#xD;
      treatment period (40 weeks), and a follow-up period (8 weeks) will be required.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Percent Change From Baseline in LDL-C at Week 12 in statin intolerance subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Percent Change From Baseline in LDL-C at Week 12 in ITT subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Change From Baseline in LDL-C at Week 12 in statin intolerance and ITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 24,52</measure>
    <time_frame>Baseline and week 24,52</time_frame>
    <description>Percent Change From Baseline in LDL-C at Week 24,52 in statin intolerance and ITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 24,52</measure>
    <time_frame>Baseline and week 24,52</time_frame>
    <description>Change From Baseline in LDL-C at Week 24,52 in statin intolerance and ITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in other lipid parameters such as non-HDL-C, ApoB, TC, et al. at Week 12, 24, 52</measure>
    <time_frame>Baseline and week 12, 24, 52</time_frame>
    <description>Percent Change From Baseline in other lipid parameters at Week 12, 24, 52 in statin intolerance and ITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With LDL-C Less Than 1.8 mmol/L(70 mg/dL)</measure>
    <time_frame>Baseline and week 12, 24, 52</time_frame>
    <description>Percentage of Participants With LDL-C Less Than 1.8 mmol/L(70 mg/dL) at Week 12, 24, 52 in statin intolerance and ITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Full Administration of JS002</measure>
    <time_frame>Baseline and week 12, 24, 52</time_frame>
    <description>Percentage of Participants With Full Administration of JS002 at Weeks 12, 24, 52 in statin intolerance and ITT subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with anti-drug antibodies (ADAs)</measure>
    <time_frame>From baseline to week 60</time_frame>
    <description>Serum samples were analyzed for ADA. Positive samples were subsequently tested for neutralizing antibodies.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">582</enrollment>
  <condition>Primary Hypercholesterolaemia and Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>JS002 150mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JS002 150mg Q2W SC for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JS002 450mg Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>JS002 450mg Q4W SC for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Q2W SC for 12 weeks, then switch to JS002 150mg Q2W SC for 40 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Q4W SC for 12 weeks, then switch to JS002 450mg Q4W SC for 40 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS002</intervention_name>
    <description>JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.</description>
    <arm_group_label>JS002 150mg Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS002</intervention_name>
    <description>JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.</description>
    <arm_group_label>JS002 450mg Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.</description>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Age 18~80 years old&#xD;
&#xD;
          3. Subject who has not achieve LDL-C goal as categorized by their CV risk at screening&#xD;
&#xD;
          4. Fasting TG≤4.5mmol/L by central laboratory at screening&#xD;
&#xD;
          5. Statin intolerance subject must have a history of statin intolerance as evidenced&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hemorrhagic stroke&#xD;
&#xD;
          2. NYHA III or IV heart failure, or known LVEF&lt; 30% within 1 year before randomization&#xD;
&#xD;
          3. Uncontrolled serious cardiac arrhythmia defined as recurrent and highly symptomatic&#xD;
             ventricular tachycardia, atrial fibrillation with rapid ventricular response, or&#xD;
             supraventricular tachycardia that are not controlled by medications, within 90 days&#xD;
             prior to randomization&#xD;
&#xD;
          4. Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),&#xD;
             coronary artery bypass graft (CABG) or stroke, deep vein thrombosis or pulmonary&#xD;
             embolism within 90 days prior to randomization&#xD;
&#xD;
          5. Planned cardiac surgery or revascularization&#xD;
&#xD;
          6. Uncontrolled hypertension defined as sitting systolic blood pressure(SBP) &gt; 160 mmHg&#xD;
             or diastolic BP (DBP) &gt; 100 mmHg&#xD;
&#xD;
          7. Type 1 diabetes, poorly controlled type 2 diabetes (HbA1c &gt; 8%), newly diagnosed type&#xD;
             2 diabetes (within 90 days of randomization)&#xD;
&#xD;
          8. Others factors not suitable for participation judged by PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiu'e Wan, PM</last_name>
    <phone>86 17710342522</phone>
    <email>qiu.e_wan@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yida Tang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

